FKBP10 (FKBP Prolyl Isomerase 10)

Furthermore, targeting FKBP10 synergized with anti-PD-1 therapy in suppressing tumor growth in vivo. Our work provides a comprehensive molecular atlas of the ccRCC ecosystem, establishes FKBP10 as a key regulator of immune suppression, and highlights its potential as a therapeutic target for personalized immunotherapy.

Clinically, the ITH signature was found to be correlated with a diminished therapeutic efficacy of both conventional transarterial chemoembolization (TACE) and immune checkpoint blockade (ICB). Our study provides a clinically actionable framework for quantifying HCC heterogeneity and reveals ECM remodeling as a potential therapeutic target in high ITH tumors, offering new avenues for personalized treatment strategies.

To the best of our knowledge, this study is the first to demonstrate the integration of S100A8 and Ki67 expression in stromal cells with histological characteristics aids in grading PT.

P=N/A, N=25, Active, not recruiting, Baylor College of Medicine | Trial completion date: Aug 2025 --> Aug 2026

Moreover, by utilizing the CIBERSORT algorithm and immunofluorescence assay, we identified and validated a significant upregulation of M0 macrophages, alongside a downregulation of activated NK cells and CD8+ T cells, which were associated with the presence of LN metastasis in BLCA. Conclusively, these results will provide new insights for future improvements in diagnosis, treatment, and prognosis evaluation for BLCA patients with LN metastasis.

Our mitochondrial-related gene signature, as a risk model, could be a reliable ccRCC prognostic biomarker and could predict the response to immunotherapy. The risk score was correlated with the tumor microenvironment and immune cell infiltration.

Comprehensive characterization of high- and low-risk groups revealed distinct patterns in pathway activation, mutational profiles, immune microenvironment composition, and therapeutic vulnerabilities. Experimental validation confirmed that the key gene FKBP10 promotes malignant phenotypes in tumor cells through IL-6/JAK/STAT3 pathway activation.

FKBP10 overexpression with TP53 mutation predicts poor prognosis and chemoresistance in TNBC. These biomarkers may guide treatment decisions, though prospective validation is needed.

In human BC tissues, nuclear lamin A is downregulated and negatively correlated with FKBP10 expression. Overall, our findings demonstrate that the FKBP10/prelamin A/lamin A axis contributes to MIBC.

Elasticnet model tuning on individual marker expression revealed top tumor predictive markers, including FKBP10, ATP1A2, NT5DC2, UGT3A2, PYCR1, CKB, GPX7, DNMT3B, GSTP1, and OXCT1. These findings indicate that an activated metabolic transcriptional program, potentially influencing epigenetic functions, is observed in hepatoblastoma tumors and confirmed at the single-cell level.

P=N/A, N=25, Active, not recruiting, Baylor College of Medicine | Trial completion date: Dec 2025 --> Aug 2025